Physician profile
Indira Chervu
NPI 1235133869
$12,143.87
in general payments reported to CMS, 2019-2025
31 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $156 · 2021: $40.01 · 2022: $221 · 2023: $508 · 2024: $326 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,434 · Consulting Fee: $2,400 · Food and Beverage: $2,214 · Education: $43.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,434.33 |
| Consulting Fee | $2,400.00 |
| Food and Beverage | $2,213.70 |
| Education | $43.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $10,416.70 | 2019-2025 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $280.53 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $192.09 | 2019-2025 | Lokelma |
| Akebia Therapeutics INC | $136.73 | 2019-2024 | Auryxia, Vafseo |
| Amgen INC. | $135.41 | 2019 | |
| Alexion Pharmaceuticals, INC. | $104.88 | 2019-2025 | Ultomiris |
| Horizon Therapeutics Plc | $95.32 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $76.24 | 2020-2025 | Terlivaz |
| Travere Therapeutics, INC. | $75.76 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.44 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $69.50 | 2024-2025 | Tarpeyo |
| Nxstage Medical, INC. | $54.02 | 2025 | Liberty Select Cycler, Nxstage System One, Nxstage Cartridge Express |
| Novartis Pharmaceuticals Corporation | $51.75 | 2025 | |
| Vifor Pharma, INC. | $43.98 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $39.49 | 2019-2024 | Rayaldee |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $28.34 | 2019 | |
| Amag Pharmaceuticals, INC. | $22.73 | 2019 | |
| Ardelyx, INC. | $22.29 | 2025 | Ibsrela |
| Novo Nordisk INC | $21.31 | 2025 | Wegovy |
| Genzyme Corporation | $20.70 | 2023 | |
| Ani Pharmaceuticals, INC. | $20.00 | 2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Glaxosmithkline, LLC. | $19.52 | 2024 | Benlysta |
| Lilly USA, LLC | $17.35 | 2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.65 | 2023 | Jardiance |
| Apellis Pharmaceuticals, INC. | $16.57 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $16.32 | 2020 | |
| Lundbeck LLC | $15.50 | 2020 | |
| Daiichi Sankyo INC. | $14.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.12 | 2019 | |
| La Jolla Pharmaceutical Company | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Chervu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.